929118-31-0

Basic information

• Product Name: N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride
• Synonyms: N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride
• CAS NO: 929118-31-0
• Molecular Weight: 312.777
• Mol File: 929118-31-0.mol

Chemical Properties

• CAS DataBase Reference: N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride(929118-31-0)
• EPA Substance Registry System: N-hydroxy-2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carboximidoyl chloride(929118-31-0)

Safety Data

• Hazardous Substances Data: 929118-31-0(Hazardous Substances Data)

Upstream product

• 929118-33-2 2-(4-isopropoxyphenoxy)-1,3-thiazole-5-carbaldehyde oxime 

Downstream Products

• 946884-21-5 2-((1R)-1-{3-[2-(4-isopropoxyphenoxy)-1,3-thiazol-5-yl]isoxazol-5-yl}ethyl)-1H-isoindole-1,3(2H)-dione 
• 946884-22-6 2-((1S)-1-{3-[2-(4-isopropoxyphenoxy)-1,3-thiazol-5-yl]isoxazol-5-yl}ethyl)-1H-isoindole-1,3(2H)-dione 
• 929118-36-5 2-(1-(3-(2-(4-isopropoxyphenoxy)thiazol-5-yl)isoxazol-5-yl)ethyl)isoindoline-1,3-dione 
• 946885-96-7 2-(1-{5-ethyl-3-[2-(4-isopropoxyphenoxy)thiazol-5-yl]isoxazol-4-yl}ethyl)isoindole-1,3-dione 
• 946885-95-6 2-(1-{4-ethyl-3-[2-(4-isopropoxyphenoxy)thiazol-5-yl]isoxazol-5-yl}ethyl)isoindole-1,3-dione 

Relevant articles and documents

NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME

The present invention relates to compounds of formula (I), which inhibit acetyl-CoA carboxylase (ACC) and are useful for the prevention or treatment of metabolic syndrome, type II diabetes, obesity, atherosclerosis and cardiovascular diseases in humans.

N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-CoA carboxylase inhibitors - Improvement of cardiovascular and neurological liabilities via structural modifications

A preliminary safety evaluation of ACC2 inhibitor 1-(S) revealed serious neurological and cardiovascular liabilities of this chemotype. A systematic structure-toxicity relationship study identified the alkyne linker as the key motif responsible for these adverse effects. Toxicogenomic studies in rats showed that 1-(R) and 1-(S) induced gene expression patterns similar to that seen with several known cardiotoxic agents such as doxorubicin. Replacement of the alkyne with alternative linker groups led to a new series of ACC inhibitors with drastically improved cardiovascular and neurological profiles.